This stands in contrast to the successes realized in developing small molecule protein kinase inhibitors to treat a number of other malignancies, including melanomas, renal cell carcinoma, chronic myelogenous leukemia, and cancers of the lung and thyroid. The gene discussed is WEE1; the disease is hereditary clear cell renal cell carcinoma.